Infertility
Conditions
Interventions
Control group:Dgestprogesterone combined with progestin vaginal sustained-release gel
Experimental group:Aloestrol tablets combined with progesterone vaginal sustained-release gel
Sponsors
The Second Affiliated Hospital Of Zhengzhou University
Eligibility
Sex/Gender
Female
Age
18 Years to 42 Years
Inclusion criteria
Inclusion criteria: 1.Women aged 18 to 42; 2.Use the agonist long regimen to promote ovulation; 3.Planning or transplantation of one or two embryos / blastocysts on fresh IVF cycles D3 or D5; 4.Hormonal tests (FSH, E2, LH, PRL, T, TSH) were normal; 5.BMI range ranges from 18 to 30 kg/m2; 6.Volunteer participate in the study and signed the informed consent;
Exclusion criteria
Exclusion criteria: 1. Known hypersensitivity to the main ingredients or excipients of allyl estradiol tablets (Dolim), dydrogesterone tablets (Daftung) or progesterone soft capsules (Angeltan); 2. Presence of any contraindication to allylsbestradiol tablets (Dolim), dydrogesterone tablets (Daftung) or progesterone soft capsules (Angeltan); 3. Unsuccessful ART embryo transfer (fresh or frozen transfer IVF cycle) > = 3 times; 4. Have a history of recurrent miscarriage (spontaneous abortion >=2 times); 5. Use of any progestogen preparation within 30 days before the egg retrieval date; 6. Acute genitourinary diseases; 7. Contraindications to pregnancy; 8. History of radiotherapy and chemotherapy; 9. Presence of any disease that may affect study completion; 10. Current or recent history of drug abuse, including alcohol and tobacco; 11. Have a history of mental disorder; 12. Participated in any other clinical trial 3 months prior to enrollment; 13. Other conditions judged by the investigator to be unsuitable for participating in this clinical study; 14. Malformations of uterine development;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Continuous pregnancy rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical pregnancy rate;Prevalence of adverse reactions;Rate of abortion;Biochemical pregnancy rate;Multifetal pregnancy rate;Healthy newborn rate;live birth rate;Incidence of adverse events (including neonatal malformations);Preterm birth rate; | — |
Countries
China
Contacts
Public ContactSong Yuxia
The Second Affiliated Hospital Of Zhengzhou University
Outcome results
None listed